Study guide

15.1 Membrane Potential, Ion Channels & Transport Mechanisms

APMLE Part I Basic Sciences Podiatry

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Lower Extremity Osteology

1.1 APMLE Part I Exam Structure, Policies & Scoring 1.2 Foot Osteology: Tarsals, Metatarsals, Phalanges & Sesamoids 1.3 Leg & Ankle Osteology: Tibia, Fibula & The Ankle Mortise 1.4 Pelvis, Femur & Patella Osteology: Landmarks & Biomechanics

2 Chapter 2: Lower Extremity Arthrology & Ligaments

2.1 Foot Articulations: Subtalar, Midtarsal, Lisfranc & Digital Joints 2.2 Talocrural (Ankle) & Knee Joints: Ligaments & Kinematics 2.3 Hip Joint & Pelvic Articulations: Capsular Structures & Dynamics

3 Chapter 3: Lower Extremity Myology & Compartments

3.1 Anterior & Lateral Compartments of the Leg 3.2 Superficial & Deep Posterior Compartments of the Leg 3.3 Plantar Layers & Intrinsic Musculature of the Foot 3.4 Thigh & Gluteal Musculature: Attachments & Innervations

4 Chapter 4: Lower Extremity Neurovascular & Topographical Anatomy

4.1 Lumbar & Sacral Plexuses, Peripheral Nerves & Dermatomes 4.2 Arterial Network, Venous Drainage & Lymphatics 4.3 Tarsal Tunnel, Femoral Triangle & Topographical Spaces

5 Chapter 5: Microbiology: Bacteriology, Zoonoses & Laboratory Methods

5.1 Gram-Positive Cocci & Bacilli in Podiatric Infections 5.2 Gram-Negative Bacilli & Opportunistic Pathogens 5.3 Anaerobic Pathogens & Diabetic Foot Infections 5.4 Bacterial Structure, Virulence Factors & Sterilization 5.5 Mycobacteria, Spirochetes, Mycoplasma & Zoonotic Infections 5.6 Antimicrobial Resistance, Susceptibility Testing, Specimen Handling & Vaccines

6 Chapter 6: Mycology, Virology, Parasitology & Clinical Immunology

6.1 Mycology: Dermatophytes, Onychomycosis & Systemic Mycoses 6.2 Clinically Relevant Viruses & Parasitic Infections 6.3 Innate & Adaptive Immunity Mechanisms 6.4 Hypersensitivity Reactions, Immunodeficiencies & Autoimmunity 6.5 Transplant & Tumor Immunology and Immunodiagnostic Methods

7 Chapter 7: General & Cellular Pathology

7.1 Cellular Injury, Adaptations & Cell Death Mechanisms 7.2 Acute vs Chronic Inflammation & Tissue Repair 7.3 Hemodynamic Disorders, Thrombosis, Embolism & Shock 7.4 Neoplasia, Oncogenes, Tumor Suppressors & Cutaneous Tumors

8 Chapter 8: Systemic & Podiatric Pathology

8.1 Atherosclerosis, Peripheral Artery Disease & Diabetic Microangiopathy 8.2 Osteoarthritis, Inflammatory Arthritides & Bone Infections 8.3 Neuropathic Disorders, Charcot Neuroarthropathy & Dermatopathology 8.4 Laboratory Diagnostics, Synovial Fluid & Biopsy Interpretation

9 Chapter 9: Organ-System Pathology

9.1 Anemias, Hemoglobinopathies, Leukemias & Immune Disorders 9.2 Cardiac & Pulmonary Pathology 9.3 Renal, Urogenital & Reproductive Pathology 9.4 Gastrointestinal, Hepatobiliary & Endocrine Pathology

10 Chapter 10: General Pharmacology, Autonomic Drugs & Toxicology

10.1 Pharmacokinetics, ADME & Receptor Dynamics 10.2 Cholinergic Agonists & Muscarinic/Nicotinic Antagonists 10.3 Adrenergic Agonists, Sympatholytics & Clinical Applications 10.4 Cardiovascular Pharmacology in Podiatric Patients 10.5 Drug Interactions, Adverse Effects, Pharmacogenomics & Toxicology

11 Chapter 11: Antimicrobial & Podiatric Therapeutics

11.1 Antibacterial Classes, Mechanisms & Resistances 11.2 Antifungal, Antiviral & Antiparasitic Therapeutics 11.3 NSAIDs, Opioids, Corticosteroids & Anti-Gout Agents 11.4 Local & General Anesthetic Pharmacology

12 Chapter 12: Systemic Pharmacology

12.1 Anticonvulsants, Antidepressants, Psychotropics & Skeletal Muscle Relaxants 12.2 Insulin & Noninsulin Glycemic Agents 12.3 Respiratory & Gastrointestinal Agents 12.4 DMARDs, Biologics, Antineoplastics & Immunosuppressants 12.5 Hormone Therapy, Bisphosphonates, Antihistamines, Growth Factors & Complementary Agents

13 Chapter 13: General Anatomy: Systemic Gross Anatomy & Neuroanatomy

13.1 Cranial Nerves, Head & Neck Anatomy 13.2 Thoracic Wall, Tracheobronchial Tree, Lungs & Mediastinum 13.3 Abdominal Wall, GI Viscera, Pelvis & Retroperitoneum 13.4 Vertebral Column, Spinal Cord & Upper Extremity Overview 13.5 Neuroanatomy: CNS Organization, Somatosensory & Motor Pathways

14 Chapter 14: Histology, Integument, Embryology & Genetics

14.1 Microscopic Anatomy: Epithelia, Connective Tissue, Muscle & Nerve 14.2 Integumentary System: Dermis, Appendages, Nail Unit & Cutaneous Receptors 14.3 Embryogenesis, Limb Morphogenesis & Postnatal Development 14.4 Medical Genetics & Structural Alterations in Aging

15 Chapter 15: Cellular, Neuromuscular & Cardiovascular Physiology

15.1 Membrane Potential, Ion Channels & Transport Mechanisms 15.2 Action Potentials, Synaptic Transmission & Muscle Contraction 15.3 Cardiac Electrophysiology, ECG & Hemodynamics 15.4 Blood Pressure Regulation, Poiseuille Law & Capillary Dynamics

16 Chapter 16: Organ-System Physiology: Respiratory, Renal, Endocrine, GI & Blood

16.1 Pulmonary Mechanics, Gas Exchange & Acid-Base Regulation 16.2 Renal Filtration, Tubular Transport & Fluid/Acid-Base Balance 16.3 Endocrine Regulation, Reproductive Hormones, Calcium & Bone 16.4 Gastrointestinal & Hepatobiliary Physiology 16.5 Hematology: Erythropoiesis, Leukocytes, Platelets & Coagulation 16.6 Exercise Physiology, Thermoregulation & Bone Mechanobiology

17 Chapter 17: Biochemistry: Proteins, Enzymes, Carbohydrates & Signaling

17.1 Amino Acid Chemistry, Protein Structure & Enzyme Kinetics 17.2 Glycolysis, Gluconeogenesis, Glycogen Metabolism & TCA Cycle 17.3 Electron Transport Chain, ATP Synthesis & Metabolic Inborn Errors 17.4 Hormones, Receptors, Second Messengers & Signal Transduction

18 Chapter 18: Biochemistry: Lipids, Molecular Genetics, Blood Chemistry & Nutrition

18.1 Fatty Acid Oxidation, Ketogenesis, Cholesterol & Lipoproteins 18.2 Nucleotide Metabolism, DNA Replication, Transcription, Translation & Repair 18.3 Vitamins, Micronutrients & Inborn Errors of Metabolism 18.4 Blood Chemistry: Heme Metabolism, Hemoglobin & Plasma Proteins 18.5 Nutrition: Energy Balance, Glycemic Index, Fed-Fast Cycle & Free Radicals

15.1 Membrane Potential, Ion Channels & Transport Mechanisms

Key Takeaways Explain This Topic AI

Resting membrane potential (-70 to -90 mV in excitable tissues) is established predominantly by high resting potassium permeability through non-gated K+ leak channels (Kir and two-pore domain K2P channels) relative to sodium (PK : PNa ≈ 100 : 1), driving Vm toward the potassium equilibrium potential (EK ≈ -95 mV), with minor electrogenic contribution from the Na+/K+ ATPase.

Passive transport encompasses simple diffusion (governed by Fick's first law and lipid partition coefficients for nonpolar gases, steroid hormones, and fat-soluble vitamins) and carrier/channel-mediated facilitated diffusion (exhibiting stereospecificity, competitive inhibition, and saturable Michaelis-Menten Vmax kinetics, as seen in GLUT1–5 uniporters and ion channels).

Primary active transport directly hydrolyzes ATP to move ions against steep electrochemical gradients: the P-type Na+/K+ ATPase exports 3 Na+ in exchange for 2 K+ per ATP hydrolyzed; cardiac glycosides (digoxin, ouabain) inhibit this pump, elevating intracellular Na+, blunting forward NCX (Na+/Ca2+ exchanger) activity, and increasing intracellular Ca2+ to boost myocardial inotropy.

Secondary active transport utilizes the electrochemical potential energy of the Na+ gradient generated by primary pumps to drive solute translocation, operating as symport/cotransport (e.g., SGLT1 in enterocytes, SGLT2 in renal proximal tubules, NKCC2 in the thick ascending limb) or antiport/countertransport (e.g., NCX 3 Na+/1 Ca2+ exchanger, NHE3 Na+/H+ exchanger).

Osmotic fluid shifts between intracellular and extracellular compartments are governed by effective osmoles with reflection coefficients (sigma) approaching 1.0 (such as Na+, glucose, and mannitol), whereas ineffective osmoles (sigma = 0, such as urea and ethanol) cross lipid bilayers freely and do not produce sustained transcellular osmotic pressure gradients or cell volume changes.

Last updated: October 2026

15.1 Membrane Potential, Ion Channels & Transport Mechanisms

Independent Study Guide Notice: Independent study guide by ExamFinch. This educational resource is developed independently by ExamFinch and is not sponsored, endorsed, or affiliated with the National Board of Podiatric Medical Examiners (NBPME) or Meazure Learning.

Introduction to Cellular Transport & Electrophysiology

Every living mammalian cell is bounded by an amphipathic lipid bilayer that establishes a distinct intracellular aqueous environment isolated from the extracellular fluid (ECF). The selective permeability of this membrane—coupled with specialized integral membrane transport proteins, ion pumps, and leak channels—generates steep asymmetric ionic concentration gradients between the intracellular fluid (ICF) and ECF. In podiatric medicine and medical basic sciences, mastery of cellular transport kinetics, resting membrane electrophysiology, and fluid-compartment osmotic equilibrium provides the essential scientific foundation for understanding local anesthetic mechanisms, peripheral nerve conduction, diabetic hyperosmolar states, diuretic pharmacology, and lower extremity compartment syndrome dynamics.

  • Resting Membrane Potential & Ion Distribution
  • Physiological Asymmetry of Transmembrane Ions

The basic biophysical engine governing all excitable tissues (neurons, skeletal myocytes, cardiomyocytes, and vascular smooth muscle) is the macroscopic separation of electrical charge across the plasma membrane. Under resting conditions, the interior of the cell maintains a net negative electrical charge relative to the extracellular fluid, termed the Resting Membrane Potential ( V m V_m V m ​ ) :

In large myelinated peripheral motor and sensory axons: V m ≈ − 70 mV V_m \approx -70\text{ mV} V m ​ ≈ − 70 mV .

In skeletal muscle fibers and ventricular cardiomyocytes: V m ≈ − 85 to − 90 mV V_m \approx -85\text{ to } -90\text{ mV} V m ​ ≈ − 85 to − 90 mV .

In small unmyelinated C-fibers and vascular smooth muscle: V m ≈ − 50 to − 60 mV V_m \approx -50\text{ to } -60\text{ mV} V m ​ ≈ − 50 to − 60 mV .

This negative voltage is maintained by dramatic disparities in the steady-state concentrations of four primary inorganic ions across the sarcolemma:

Ion Species Extracellular Concentration ( [ Ion ] o [\text{Ion}]_o [ Ion ] o ​ ) Intracellular Concentration ( [ Ion ] i [\text{Ion}]_i [ Ion ] i ​ ) Concentration Ratio ( [ o ] / [ i ] [o]/[i] [ o ] / [ i ] ) Equilibrium Potential ( E ion E_{\text{ion}} E ion ​ at 37°C)

Potassium ( K + K^+ K + ) 4.0 − 5.0 mEq/L 4.0 - 5.0\text{ mEq/L} 4.0 − 5.0 mEq/L 140 − 150 mEq/L 140 - 150\text{ mEq/L} 140 − 150 mEq/L ≈ 1 : 30 \approx 1 : 30 ≈ 1 : 30 − 90 to − 95 mV -90\text{ to } -95\text{ mV} − 90 to − 95 mV

Sodium ( N a + Na^+ N a + ) 135 − 145 mEq/L 135 - 145\text{ mEq/L} 135 − 145 mEq/L 10 − 14 mEq/L 10 - 14\text{ mEq/L} 10 − 14 mEq/L ≈ 10 : 1 \approx 10 : 1 ≈ 10 : 1 + 60 to + 65 mV +60\text{ to } +65\text{ mV} + 60 to + 65 mV

Chloride ( C l − Cl^- C l − ) 98 − 106 mEq/L 98 - 106\text{ mEq/L} 98 − 106 mEq/L 4 − 10 mEq/L 4 - 10\text{ mEq/L} 4 − 10 mEq/L ≈ 15 : 1 \approx 15 : 1 ≈ 15 : 1 − 70 to − 85 mV -70\text{ to } -85\text{ mV} − 70 to − 85 mV

Ionized Calcium ( C a 2 + Ca^{2+} C a 2 + ) 1.1 − 1.3 mM 1.1 - 1.3\text{ mM} 1.1 − 1.3 mM ( 2.2 − 2.6 mEq/L 2.2 - 2.6\text{ mEq/L} 2.2 − 2.6 mEq/L ) 0.0001 mM 0.0001\text{ mM} 0.0001 mM ( 100 nM 100\text{ nM} 100 nM ) ≈ 10 , 000 : 1 \approx 10,000 : 1 ≈ 10 , 000 : 1 + 120 to + 130 mV +120\text{ to } +130\text{ mV} + 120 to + 130 mV

The Nernst Equation: Equilibrium Potentials

For any single permeant ion species, two opposing forces govern transcellular movement:

A chemical concentration gradient driving diffusion from high concentration to low concentration.

An electrical potential gradient driving movement of charged particles toward an oppositely charged compartment.

When the electrical force exactly balances the chemical diffusion force, net transcellular flux of that ion ceases. The electrical potential at which this thermodynamic equilibrium occurs is the Equilibrium Potential ( E ion E_{\text{ion}} E ion ​ ) , formulated by Walther Nernst in the Nernst Equation :

E ion = R T z F ln ⁡ ( [ ion ] o [ ion ] i ) E_{\text{ion}} = \frac{RT}{zF} \ln\left(\frac{[\text{ion}]_o}{[\text{ion}]_i}\right) E ion ​ = z F RT ​ ln ( [ ion ] i ​ [ ion ] o ​ ​ )

Where:

R R R is the universal gas constant ( 8.314 J / ( mol ⋅ K ) 8.314\text{ J}/(\text{mol}\cdot\text{K}) 8.314 J / ( mol ⋅ K ) ).

T T T is absolute temperature in Kelvin ( 310.15 K 310.15\text{ K} 310.15 K at physiological body temperature 37 ∘ C 37^\circ\text{C} 3 7 ∘ C ).

z z z is the valence (electrical charge) of the ion ( + 1 +1 + 1 for N a + Na^+ N a + and K + K^+ K + ; + 2 +2 + 2 for C a 2 + Ca^{2+} C a 2 + ; − 1 -1 − 1 for C l − Cl^- C l − ).

F F F is Faraday's constant ( 96 , 485 C / mol 96,485\text{ C}/\text{mol} 96 , 485 C / mol ).

Converting natural logarithms to base-10 logarithms ( ln ⁡ ( x ) = 2.3026 × log ⁡ 10 ( x ) \ln(x) = 2.3026 \times \log_{10}(x) ln ( x ) = 2.3026 × lo g 10 ​ ( x ) ) and consolidating physical constants at 37 ∘ C 37^\circ\text{C} 3 7 ∘ C yields the simplified clinical board formula:

E ion = 61.5 z log ⁡ 10 ( [ ion ] o [ ion ] i ) E_{\text{ion}} = \frac{61.5}{z} \log_{10}\left(\frac{[\text{ion}]_o}{[\text{ion}]_i}\right) E ion ​ = z 61.5 ​ lo g 10 ​ ( [ ion ] i ​ [ ion ] o ​ ​ )

Applying this formula demonstrates why potassium dominates the resting cell potential:

For Potassium ( z = + 1 z = +1 z = + 1 ): E K = 61.5 log ⁡ 10 ( 4 / 140 ) = 61.5 log ⁡ 10 ( 0.02857 ) = 61.5 × ( − 1.544 ) ≈ − 95 mV E_K = 61.5 \log_{10}(4 / 140) = 61.5 \log_{10}(0.02857) = 61.5 \times (-1.544) \approx -95\text{ mV} E K ​ = 61.5 lo g 10 ​ ( 4/140 ) = 61.5 lo g 10 ​ ( 0.02857 ) = 61.5 × ( − 1.544 ) ≈ − 95 mV .

For Sodium ( z = + 1 z = +1 z = + 1 ): E N a = 61.5 log ⁡ 10 ( 142 / 14 ) = 61.5 log ⁡ 10 ( 10.14 ) = 61.5 × ( + 1.006 ) ≈ + 62 mV E_{Na} = 61.5 \log_{10}(142 / 14) = 61.5 \log_{10}(10.14) = 61.5 \times (+1.006) \approx +62\text{ mV} E N a ​ = 61.5 lo g 10 ​ ( 142/14 ) = 61.5 lo g 10 ​ ( 10.14 ) = 61.5 × ( + 1.006 ) ≈ + 62 mV .

For Calcium ( z = + 2 z = +2 z = + 2 ): E C a = 61.5 2 log ⁡ 10 ( 1.2 / 0.0001 ) = 30.75 log ⁡ 10 ( 12 , 000 ) = 30.75 × 4.079 ≈ + 125 mV E_{Ca} = \frac{61.5}{2} \log_{10}(1.2 / 0.0001) = 30.75 \log_{10}(12,000) = 30.75 \times 4.079 \approx +125\text{ mV} E C a ​ = 2 61.5 ​ lo g 10 ​ ( 1.2/0.0001 ) = 30.75 lo g 10 ​ ( 12 , 000 ) = 30.75 × 4.079 ≈ + 125 mV .

For Chloride ( z = − 1 z = -1 z = − 1 ): E C l = 61.5 − 1 log ⁡ 10 ( 103 / 5 ) = − 61.5 log ⁡ 10 ( 20.6 ) = − 61.5 × 1.314 ≈ − 81 mV E_{Cl} = \frac{61.5}{-1} \log_{10}(103 / 5) = -61.5 \log_{10}(20.6) = -61.5 \times 1.314 \approx -81\text{ mV} E Cl ​ = − 1 61.5 ​ lo g 10 ​ ( 103/5 ) = − 61.5 lo g 10 ​ ( 20.6 ) = − 61.5 × 1.314 ≈ − 81 mV .

The Goldman-Hodgkin-Katz (GHK) Voltage Equation

Under physiological resting conditions, biological membranes are not exclusively permeable to a single ion; rather, multiple ions permeate simultaneously through open channels. The actual steady-state resting membrane potential ( V m V_m V m ​ ) is therefore a weighted compromise between the equilibrium potentials of all permeant ions, weighted by their respective membrane permeabilities ( P P P ) . This relationship is quantified by the Goldman-Hodgkin-Katz (GHK) Equation :

V m = R T F ln ⁡ ( P K [ K + ] o + P N a [ N a + ] o + P C l [ C l − ] i P K [ K + ] i + P N a [ N a + ] i + P C l [ C l − ] o ) V_m = \frac{RT}{F} \ln\left( \frac{P_K [K^+]_o + P_{Na} [Na^+]_o + P_{Cl} [Cl^-]_i}{P_K [K^+]_i + P_{Na} [Na^+]_i + P_{Cl} [Cl^-]_o} \right) V m ​ = F RT ​ ln ( P K ​ [ K + ] i ​ + P N a ​ [ N a + ] i ​ + P Cl ​ [ C l − ] o ​ P K ​ [ K + ] o ​ + P N a ​ [ N a + ] o ​ + P Cl ​ [ C l − ] i ​ ​ )

(Note that intracellular [ C l − ] i [Cl^-]_i [ C l − ] i ​ appears in the numerator and extracellular [ C l − ] o [Cl^-]_o [ C l − ] o ​ appears in the denominator because chloride carries a negative valence, z = − 1 z = -1 z = − 1 ).

In a resting nerve or skeletal muscle membrane, non-gated potassium leak channels (principally inwardly rectifying potassium channels [ K i r K_{ir} K i r ​ ] and tandem-pore domain potassium channels [ K 2 P K_{2P} K 2 P ​ ] such as TASK and TREK) remain constitutively open. In contrast, resting voltage-gated N a + Na^+ N a + and C a 2 + Ca^{2+} C a 2 + channels remain firmly closed. Consequently, the resting relative permeability ratio is approximately:

P K : P N a : P C l ≈ 1.0 : 0.04 : 0.45 P_K : P_{Na} : P_{Cl} \approx 1.0 : 0.04 : 0.45 P K ​ : P N a ​ : P Cl ​ ≈ 1.0 : 0.04 : 0.45

Because P K P_K P K ​ is roughly 25 to 100 times greater than P N a P_{Na} P N a ​ , the resting membrane potential is drawn overwhelmingly toward E K E_K E K ​ ( − 95 mV -95\text{ mV} − 95 mV ), settling comfortably between − 70 mV -70\text{ mV} − 70 mV and − 90 mV -90\text{ mV} − 90 mV . The slight deviation from E K E_K E K ​ toward zero is caused by a small, continuous background influx of N a + Na^+ N a + through baseline leak pathways.

Electrogenic Contribution of the N a + / K + Na^+/K^+ N a + / K + ATPase

If ions permeated passively through leak channels without counter-regulation, concentration gradients would eventually dissipate, causing V m V_m V m ​ to collapse to 0 mV 0\text{ mV} 0 mV (Donnan equilibrium) and producing fatal osmotic swelling and cellular lysis. The primary active N a + / K + Na^+/K^+ N a + / K + ATPase (sodium-potassium pump) continuously counteracts passive leak by expelling 3 N a + 3\text{ }Na^+ 3 N a + ions into the ECF for every 2 K + 2\text{ }K^+ 2 K + ions imported into the ICF per molecule of ATP hydrolyzed:

By pumping 3 positive charges out for every 2 positive charges in, the pump generates a net outward current of 1 positive charge per cycle.

This direct electrogenic effect contributes approximately − 4 to − 10 mV -4\text{ to } -10\text{ mV} − 4 to − 10 mV directly to the resting membrane potential.

Far more importantly, by continuously extruding N a + Na^+ N a + and accumulating K + K^+ K + , the pump maintains the steep concentration gradients without which P K P_K P K ​ could not generate the Nernstian diffusion potential. Resting Membrane Potential Dynamics

  • EXTRACELLULAR FLUID (ECF) INTRACELLULAR FLUID (ICF)
  • [Na+] = 142 mEq/L [Na+] = 14 mEq/L
  • [K+] = 4 mEq/L [K+] = 140 mEq/L
  • [Cl-] = 103 mEq/L [Cl-] = 5 mEq/L
  • [Ca2+]= 1.2 mM [Ca2+]= 0.0001 mM
  • ───────────────────────────────────────────────────────────────
  • │ ▲
  • │ Passive Na+ Leak (Minor) │ Massive K+ Leak
  • │ (P_Na = 0.04) │ (P_K = 1.00 via K2P/Kir)
  • ▼ │
  • ═══════════════════════════════════════════════════════════════
  • PLASMA MEMBRANE (Lipid Bilayer: Vm = -70 to -90 mV)
  • ═══════════════════════════════════════════════════════════════
  • ▲ │
  • │ ┌────────────────────────┐ ▼
  • └─────┤ Na+/K+ ATPase Pump ├──────┘
  • 3 Na+ │ - Hydrolyzes 1 ATP │ 2 K+
  • OUT │ - Electrogenic (-5 mV) │ IN
  • └────────────────────────┘
  • Passive Transport: Simple vs. Facilitated Diffusion

Passive transport describes the net translocation of chemical solutes across a biological membrane down an electrochemical or concentration gradient without the expenditure of metabolic energy (ATP). Passive transport is subclassified into simple diffusion and facilitated diffusion :

Simple Diffusion & Fick's First Law

Simple diffusion involves the unassisted, non-carrier-mediated movement of solutes directly through the hydrophobic core of the phospholipid bilayer. The rate of net diffusion ( J J J , flux in mol / ( cm 2 ⋅ s ) \text{mol}/(\text{cm}^2\cdot\text{s}) mol / ( cm 2 ⋅ s ) ) across a planar membrane is described by Fick's First Law of Diffusion :

J = − D d C d x J = -D \frac{dC}{dx} J = − D d x d C ​

When applied to biological membranes with a fixed thickness ( Δ x \Delta x Δ x ), Fick's law is expressed clinically as:

J = P ⋅ A ⋅ ( C 1 − C 2 ) J = P \cdot A \cdot (C_1 - C_2) J = P ⋅ A ⋅ ( C 1 ​ − C 2 ​ )

Where:

P P P is the membrane permeability coefficient ( cm / s \text{cm}/\text{s} cm / s ).

A A A is the total functional surface area of the membrane available for diffusion ( cm 2 \text{cm}^2 cm 2 ).

( C 1 − C 2 ) (C_1 - C_2) ( C 1 ​ − C 2 ​ ) is the transcellular concentration gradient between compartments.

The permeability coefficient ( P P P ) reflects intrinsic biophysical properties of both the solute and the lipid bilayer:

P = K p ⋅ D Δ x P = \frac{K_p \cdot D}{\Delta x} P = Δ x K p ​ ⋅ D ​

Oil/Water Partition Coefficient ( K p K_p K p ​ ): A measure of lipid solubility. Solutes with high K p K_p K p ​ (lipophilic/hydrophobic molecules) dissolve readily into the hydrocarbon core of the membrane and diffuse with high velocity. Examples include gases ( O 2 , C O 2 , N 2 O_2, CO_2, N_2 O 2 ​ , C O 2 ​ , N 2 ​ ) , steroid hormones (cortisol, aldosterone, testosterone, estrogen), fat-soluble vitamins (A, D, E, K), and uncharged lipophilic local anesthetics (e.g., non-ionized lidocaine base).

Molecular Radius / Size ( D D D ): Smaller molecules diffuse faster than bulky, high-molecular-weight compounds. The diffusion coefficient D D D is inversely proportional to molecular radius ( D ∝ 1 / r D \propto 1 / r D ∝ 1/ r ).

Membrane Thickness ( Δ x \Delta x Δ x ): Increasing the diffusion distance (such as in peripheral diabetic microangiopathic basement membrane thickening or pulmonary interstitial fibrosis) directly decreases diffusion flux ( J ∝ 1 / Δ x J \propto 1 / \Delta x J ∝ 1/Δ x ).

Key Kinetic Characteristic: Simple diffusion exhibits non-saturable linear kinetics . As the concentration gradient ( C 1 − C 2 ) (C_1 - C_2) ( C 1 ​ − C 2 ​ ) increases, the rate of transport rises indefinitely without reaching a plateau or maximum velocity ( V m a x V_{max} V ma x ​ ).

Facilitated Diffusion: Carrier-Mediated & Channel-Mediated Transport

Hydrophilic, polar, or charged solutes (such as glucose, amino acids, and inorganic cations) exhibit vanishingly low lipid partition coefficients ( K p ≈ 0 K_p \approx 0 K p ​ ≈ 0 ) and cannot penetrate the hydrophobic core of the bilayer. These solutes require specialized transmembrane integral proteins that provide an aqueous, shielded pathway across the membrane. Facilitated diffusion proceeds strictly down the solute's electrochemical gradient and requires no ATP.

Carrier-mediated facilitated transport is distinguished by three cardinal physiological hallmarks:

Stereospecificity: Transport carriers exhibit precise conformational recognition. For example, glucose transporters transport biologically active D-glucose rapidly while completely ignoring its optical stereoisomer L-glucose .

Saturation Kinetics ( V m a x V_{max} V ma x ​ ): The membrane contains a finite, stoichiometric number of carrier proteins. At low solute concentrations, transport velocity rises rapidly. However, once all solute-binding sites become fully occupied, the transport rate reaches an asymptote termed the maximal transport velocity ( V m a x V_{max} V ma x ​ ) , following classic Michaelis-Menten saturation kinetics. The solute concentration that yields half-maximal velocity is the affinity constant ( K m K_m K m ​ ).

Competitive & Non-Competitive Inhibition: Structurally related chemical analogues compete for the same binding pocket, shifting the apparent K m K_m K m ​ to higher concentrations (e.g., D-galactose competitively inhibits D-glucose transport).

The Glucose Transporter (GLUT) Family

In human physiology, facilitative glucose transport is executed by the GLUT (SLC2A) family of facilitative uniporters, which span the plasma membrane with 12 transmembrane α \alpha α -helices:

Transporter Tissue Distribution Biochemical Properties ( K m K_m K m ​ ) Physiological & Clinical Significance

GLUT1 Erythrocytes, blood-brain barrier (cerebral capillary endothelium), renal podocytes, perineurium High affinity ( K m ≈ 1 − 2 mM K_m \approx 1-2\text{ mM} K m ​ ≈ 1 − 2 mM ) Provides basal, uninterrupted glucose uptake to vital tissues; deficient in GLUT1 deficiency syndrome (infantile seizures, microcephaly)

GLUT2 Hepatocytes, pancreatic β \beta β -islet cells, renal proximal tubule (basolateral), small intestinal enterocyte (basolateral) Low affinity, high capacity ( K m ≈ 15 − 20 mM K_m \approx 15-20\text{ mM} K m ​ ≈ 15 − 20 mM ) Functions as a physiological glucose sensor in pancreatic β \beta β -cells (triggering insulin exocytosis); bidirectional hepatic glucose release during fasting; mutated in Fanconi-Bickel syndrome

GLUT3 Neurons, cerebral cortex, peripheral axons Extraordinary high affinity ( K m < 1 mM K_m < 1\text{ mM} K m ​ < 1 mM ) Guarantees continuous cerebral and neural glucose delivery even during severe systemic hypoglycemia

GLUT4 Skeletal muscle , cardiac muscle , adipose tissue Medium-to-high affinity ( K m ≈ 5 mM K_m \approx 5\text{ mM} K m ​ ≈ 5 mM ) The ONLY insulin-dependent glucose transporter. In the basal state, sequestered inside intracellular tubulovesicular endosomes. Insulin binding to tyrosine kinase receptor triggers IRS-1/PI3K/AKT cascade, mobilizing GLUT4 translocation to the sarcolemma. Muscular contraction during exercise independently mobilizes GLUT4 via 5 ′ 5' 5 ′ -AMP-activated protein kinase (AMPK), forming the basis for exercise-mediated glycemic control in diabetic patients

GLUT5 Small intestinal brush border (apical), spermatozoa, renal tubular epithelium Specific for fructose ( K m ≈ 6 − 10 mM K_m \approx 6-10\text{ mM} K m ​ ≈ 6 − 10 mM ) Does NOT transport glucose or galactose ; exclusive facilitative fructose uniporter; involved in dietary fructose malabsorption syndromes GLUT4 Translocation in Skeletal Muscle

  • INSULIN MUSCULAR EXERCISE
  • │ │
  • ▼ ▼
  • [Insulin Receptor] [Contraction / High AMP]
  • (Tyrosine Kinase) │
  • │ ▼
  • ▼ [ AMPK ]
  • [IRS-1 / PI3K] │
  • │ │
  • ▼ │
  • [ AKT ] ──────────────────────────────────┘
  • │
  • ▼
  • ┌───────────────────────────┐
  • │ Mobilizes GLUT4 Storage │
  • │ Vesicles (GSVs) │
  • └────────────┬──────────────┘
  • │ Exocytic Translocation
  • ▼
  • ═══════════════════════════════════════════════════════════════
  • SARCOLEMMA (Skeletal Muscle Plasma Membrane)
  • ═══════════════════════════════════════════════════════════════
  • [GLUT4] [GLUT4] [GLUT4] <── Translocated Uniporters
  • │ │ │
  • ▼ ▼ ▼
  • Extracellular D-Glucose Enters Sarcoplasm Down Gradient

Active Transport: Primary vs. Secondary Mechanisms

Active transport is the carrier-mediated movement of solutes uphill against an electrochemical or concentration gradient ( d C / d x > 0 dC/dx > 0 d C / d x > 0 or against opposing voltage). Because moving molecules against thermodynamic equilibrium requires energy, active transport must couple to an exergonic energy source.

Primary Active Transport (ATP Hydrolysis)

Primary active transport couples solute movement directly to the cleavage of high-energy phosphate bonds from adenosine triphosphate ( ATP → ADP + P i \text{ATP} \to \text{ADP} + P_i ATP → ADP + P i ​ ). The primary transport proteins are P-type, V-type, and ABC ATPases:

P-Type ATPases: Form a phosphorylated aspartyl-phosphate intermediate ( E 1 ∼ P E_1 \sim P E 1 ​ ∼ P and E 2 ∼ P E_2 \sim P E 2 ​ ∼ P ) during the catalytic reaction cycle:

N a + / K + Na^+/K^+ N a + / K + ATPase: Ubiquitous across all animal cells. Maintains resting membrane potential, sustains osmotic cell volume, and generates the driving force for all secondary active transport.

SERCA ( C a 2 + Ca^{2+} C a 2 + -ATPase of Sarcoplasmic/Endoplasmic Reticulum): Rapidly clears free C a 2 + Ca^{2+} C a 2 + from the cytoplasm into the SR lumen ( 2 C a 2 + 2\text{ }Ca^{2+} 2 C a 2 + per ATP) to permit striated muscle relaxation; in cardiomyocytes, SERCA2a is reversibly regulated by phospholamban .

PMCA (Plasma Membrane C a 2 + Ca^{2+} C a 2 + -ATPase): Expels C a 2 + Ca^{2+} C a 2 + across the sarcolemma into the ECF ( 1 C a 2 + 1\text{ }Ca^{2+} 1 C a 2 + per ATP); high affinity, low capacity system for fine resting calcium homeostasis.

H + / K + H^+/K^+ H + / K + ATPase (Proton Pump): Present on the apical canalicular membrane of gastric parietal cells (secretes H + H^+ H + at pH 0.8 \text{pH } 0.8 pH 0.8 in exchange for luminal K + K^+ K + ) and renal α \alpha α -intercalated cells (urinary acidification). Pharmacologically inhibited by Proton Pump Inhibitors (PPIs) such as omeprazole and pantoprazole.

V-Type (Vacuolar) H + H^+ H + ATPases: Multi-subunit rotary proton pumps that do not form a phosphorylated intermediate. Located within membranes of lysosomes, endosomes, and synaptic vesicles to maintain an acidic luminal pH ( pH 4.5 − 5.5 \,\text{pH } 4.5-5.5 pH 4.5 − 5.5 ). Crucially, V-type proton pumps are expressed on the ruffled border of osteoclasts , pumping protons into Howship lacunae to dissolve calcium hydroxyapatite bone mineral during osseous remodeling.

ABC (ATP-Binding Cassette) Transporters: Utilize dual nucleotide-binding domains to transport organic macromolecules. Classic examples include MDR1 (P-glycoprotein / ABCB1) , which expels lipophilic drugs and xenobiotics (responsible for multidrug resistance in oncology), and CFTR (ABCC7) , a unique ATP-gated chloride channel mutated in cystic fibrosis.

Mechanism of Cardiac Glycosides (Digoxin & Ouabain)

Cardiac glycosides exert their powerful inotropic effects on the failing myocardium through primary inhibition of the N a + / K + Na^+/K^+ N a + / K + ATPase:

Digoxin binds reversibly to the extracellular K + K^+ K + -binding domain of the phosphorylated E 2 − P E_2-P E 2 ​ − P conformation of the myocardial N a + / K + Na^+/K^+ N a + / K + ATPase.

Pump inhibition halts N a + Na^+ N a + extrusion, causing intracellular [ N a + ] i [Na^+]_i [ N a + ] i ​ to rise from its baseline of 10 mEq/L 10\text{ mEq/L} 10 mEq/L to 15 − 20 mEq/L 15-20\text{ mEq/L} 15 − 20 mEq/L .

This localized accumulation of intracellular sodium drastically collapses the transmembrane electrochemical N a + Na^+ N a + gradient.

As a direct consequence, the N a + / C a 2 + Na^+/Ca^{2+} N a + / C a 2 + Exchanger (NCX) —a secondary active antiporter that relies on the inward N a + Na^+ N a + gradient to expel intracellular C a 2 + Ca^{2+} C a 2 + —is severely blunted or operates transiently in reverse.

Cytoplasmic C a 2 + Ca^{2+} C a 2 + clearance is impaired, allowing the sarcoplasmic reticulum ( S R SR SR ) to sequester larger-than-normal quantities of C a 2 + Ca^{2+} C a 2 + via SERCA2a.

Upon arrival of the next cardiac action potential, the massive accumulated SR calcium stores are released through Ryanodine Receptors (RyR2) via Calcium-Induced Calcium Release (CICR) , generating a substantial increase in cross-bridge cycling and a dramatic boost in myocardial contractile force (positive inotropy) .

Important

Digoxin Toxicity & Serum Potassium Interplay: Because digoxin and extracellular K + K^+ K + ions compete for the same binding site on the external face of the N a + / K + Na^+/K^+ N a + / K + ATPase, hypokalemia (frequently caused by concurrent loop or thiazide diuretic therapy) removes competitive inhibition, allowing digoxin to bind unchecked and precipitating fatal digoxin toxicity (visual yellow-green halos / xanthopsia, nausea, bidirectional ventricular tachycardia, and junctional escape rhythms). Conversely, massive acute digoxin overdose completely paralyzes N a + / K + Na^+/K^+ N a + / K + pumps systemic-wide, preventing cellular K + K^+ K + uptake and producing life-threatening hyperkalemia . Myocardial Digoxin & NCX Inotropic Cascade

  • EXTRACELLULAR FLUID CARDIOMYOCYTE SARCOPLASM
  • ─────────────────────────────────────────────────────────────────
  • [ DIGOXIN ]
  • │
  • ▼ Inhibits
  • ┌─────────────────┐
  • │ Na+/K+ ATPase │ ──(Halts Na+ Extrusion)──► [Na+]_i Rises
  • └─────────────────┘ │
  • ▼
  • ┌─────────────────┐ Blunts Inward Na+
  • │ NCX Antiporter │ ◄─────────────────── Driving Force
  • │ (3 Na+ : 1 Ca2+)│
  • └────────┬────────┘
  • │ (Decreased Ca2+ Extrusion)
  • ▼
  • [Ca2+]_i Rises
  • │
  • ▼ Sequestered via SERCA2a
  • ┌───────────────────────┐
  • │ Sarcoplasmic Reticulum│ ──(Action Potential)──► Massive CICR via RyR2
  • │ Massive Ca2+ Stores │ │
  • └───────────────────────┘ ▼
  • DRAMATIC POSITIVE INOTROPY
  • (Increased Stroke Volume)
  • Secondary Active Transport (Coupled Transporters)

Secondary active transport couples the downhill movement of an "energizing" driver ion (almost universally N a + Na^+ N a + in mammalian systems) down its steep electrochemical gradient to the simultaneous uphill movement of a second "cargo" solute against its concentration gradient. The cell expends ATP indirectly , because the driving N a + Na^+ N a + gradient must be continuously replenished by the primary active N a + / K + Na^+/K^+ N a + / K + ATPase.

Secondary active transport is categorized into two mechanical configurations:

1. Symport (Cotransport)

The driver ion and cargo solute travel across the plasma membrane in the same physical direction :

SGLT1 ( N a + Na^+ N a + /Glucose Cotransporter 1): Located in the apical brush border of intestinal enterocytes; translocates 2 N a + 2\text{ }Na^+ 2 N a + ions inward alongside 1 molecule 1\text{ molecule} 1 molecule of D-glucose or D-galactose against an uphill gradient (high intracellular sugar concentration). Powered by basolateral N a + / K + Na^+/K^+ N a + / K + pumping.

SGLT2 ( N a + Na^+ N a + /Glucose Cotransporter 2): Located on the apical brush border of the early proximal convoluted tubule (S1 and S2 segments) of the nephron. Couples 1 N a + 1\text{ }Na^+ 1 N a + to 1 D-glucose 1\text{ }\text{D-glucose} 1 D-glucose to reabsorb > 90 % >90\% > 90% of all filtered glucose. Pharmacologically blocked by gliflozins (empagliflozin, dapagliflozin, canagliflozin) , promoting glycosuria to reduce glycated hemoglobin ( H b A 1 c HbA1c H b A 1 c ), lower systemic arterial pressure, and confer profound renal and cardiovascular protection.

NKCC2 ( N a + / K + / 2 C l − Na^+/K^+/2Cl^- N a + / K + /2 C l − Cotransporter): Localized to the apical membrane of the thick ascending limb of the loop of Henle. Electroneutrally transports 1 N a + 1\text{ }Na^+ 1 N a + , 1 K + 1\text{ }K^+ 1 K + , and 2 C l − 2\text{ }Cl^- 2 C l − into the tubular cell. Driven by basolateral N a + / K + Na^+/K^+ N a + / K + ATPase; targeted and blocked by loop diuretics (furosemide, bumetanide, torsemide) , abolishing the medullary hypertonic concentration gradient and inducing vigorous natriuresis and diuresis.

NCC ( N a + / C l − Na^+/Cl^- N a + / C l − Cotransporter): Apical membrane of the distal convoluted tubule; reabsorbs 1 N a + 1\text{ }Na^+ 1 N a + with 1 C l − 1\text{ }Cl^- 1 C l − . Inhibited by thiazide diuretics (hydrochlorothiazide, chlorthalidone) ; mutated in Gitelman syndrome.

2. Antiport (Countertransport / Exchange)

The driver ion and cargo solute travel across the plasma membrane in opposite physical directions :

NCX ( N a + / C a 2 + Na^+/Ca^{2+} N a + / C a 2 + Exchanger): Found prominently in cardiac sarcolemma, vascular smooth muscle, and neurons. Translocates 3 N a + 3\text{ }Na^+ 3 N a + inward down their electrochemical gradient in exchange for 1 C a 2 + 1\text{ }Ca^{2+} 1 C a 2 + outward against its gradient. Electrogenic (net 1 positive charge enters the cell per cycle). Essential for diastolic C a 2 + Ca^{2+} C a 2 + clearance.

NHE3 ( N a + / H + Na^+/H^+ N a + / H + Exchanger 3): Located on the apical brush border of the renal proximal convoluted tubule. Expels 1 H + 1\text{ }H^+ 1 H + into the tubular lumen to drive luminal H C O 3 − HCO_3^- H C O 3 − ​ reabsorption in exchange for 1 N a + 1\text{ }Na^+ 1 N a + reabsorbed into the cytoplasm. Directly stimulated by Angiotensin II to sustain intravascular volume during states of hypoperfusion.

Transport Mechanism Primary Energy Source Solute Trajectory Kinetics Canonical Human Examples Pharmacological / Clinical Correlate

Simple Diffusion Kinetic thermal energy Down gradient ( − Δ C -\Delta C − Δ C ) Linear (non-saturable, no V m a x V_{max} V ma x ​ ) O 2 , C O 2 , N 2 O_2, CO_2, N_2 O 2 ​ , C O 2 ​ , N 2 ​ , steroid hormones, ethanol Impaired in diabetic microangiopathy and tissue hypoxia

Facilitated Diffusion Electrochemical gradient Down gradient ( − Δ C -\Delta C − Δ C ) Saturable ( V m a x , K m V_{max}, K_m V ma x ​ , K m ​ ), stereospecific GLUT1 (RBC/BBB), GLUT4 (muscle/fat) Insulin stimulates GLUT4 vesicle exocytosis in skeletal muscle

Primary Active Transport Direct ATP hydrolysis Uphill against gradient ( + Δ C +\Delta C + Δ C ) Saturable ( V m a x V_{max} V ma x ​ ), requires ATPase phosphorylation N a + / K + Na^+/K^+ N a + / K + ATPase, SERCA, Gastric H + / K + H^+/K^+ H + / K + ATPase Digoxin inhibits N a + / K + Na^+/K^+ N a + / K + ATPase; PPIs inhibit gastric H + / K + H^+/K^+ H + / K + pump

Secondary Active: Symport Electrochemical N a + Na^+ N a + gradient Uphill, same direction as N a + Na^+ N a + Saturable ( V m a x V_{max} V ma x ​ ), couples to N a + Na^+ N a + inward flux SGLT2 (renal proximal tubule), NKCC2 (loop of Henle) Empagliflozin blocks SGLT2; Furosemide blocks NKCC2

Secondary Active: Antiport Electrochemical N a + Na^+ N a + gradient Uphill, opposite direction to N a + Na^+ N a + Saturable ( V m a x V_{max} V ma x ​ ), electrogenic or electroneutral NCX ( 3 N a + : 1 C a 2 + 3 Na^+ : 1 Ca^{2+} 3 N a + : 1 C a 2 + ), NHE3 ( 1 N a + : 1 H + 1 Na^+ : 1 H^+ 1 N a + : 1 H + ) NCX blunted by digitalis; NHE3 stimulated by Angiotensin II

  • Osmolarity, Osmolality & Capillary Tonicity Dynamics
  • Osmolarity vs. Osmolality

Water is the universal solvent of biological systems, moving effortlessly through cell membranes via specialized bidirectional water channels termed aquaporins (AQP1-4) . The chemical driving force for water flux is the absolute concentration of dissolved solute particles:

Osmolarity: The number of osmoles of solute per liter of solution ( Osm/L \text{Osm/L} Osm/L or mOsm/L \text{mOsm/L} mOsm/L ). Because liquid volume expands and contracts with changes in temperature and ambient pressure, osmolarity varies slightly under physiological extremes.

Osmolality: The number of osmoles of solute per kilogram of solvent ( Osm/kg \text{Osm/kg} Osm/kg or mOsm/kg \text{mOsm/kg} mOsm/kg ). Osmolality is temperature-independent and represents the precise laboratory standard measured via freezing-point depression osmometry.

In dilute clinical biological fluids, 1 liter of water ≈ 1 kilogram of water 1\text{ liter of water} \approx 1\text{ kilogram of water} 1 liter of water ≈ 1 kilogram of water , so osmolarity and osmolality are numerically almost interchangeable. Normal human plasma osmolality is tightly defended within a narrow homeostatic window of 285 − 295 mOsm/kg 285 - 295\text{ mOsm/kg} 285 − 295 mOsm/kg .

Clinical Plasma Osmolality Calculation & Osmolar Gap

Under physiological conditions, sodium and its accompanying anions ( C l − , H C O 3 − Cl^-, HCO_3^- C l − , H C O 3 − ​ ) account for > 90 % >90\% > 90% of total extracellular osmolality, with small contributions from glucose and blood urea nitrogen (BUN):

Calculated Serum Osmolality ( mOsm/kg ) = 2 × [ N a + ] + [ Glucose (mg/dL) ] 18 + [ BUN (mg/dL) ] 2.8 \text{Calculated Serum Osmolality } (\text{mOsm/kg}) = 2 \times [Na^+] + \frac{[\text{Glucose (mg/dL)}]}{18} + \frac{[\text{BUN (mg/dL)}]}{2.8} Calculated Serum Osmolality ( mOsm/kg ) = 2 × [ N a + ] + 18 [ Glucose (mg/dL) ] ​ + 2.8 [ BUN (mg/dL) ] ​

The divisor 18 18 18 converts glucose from mg/dL \text{mg/dL} mg/dL to mmol/L \text{mmol/L} mmol/L (molecular weight of glucose ≈ 180 g/mol \approx 180\text{ g/mol} ≈ 180 g/mol ).

The divisor 2.8 2.8 2.8 converts BUN from mg/dL \text{mg/dL} mg/dL of nitrogen to mmol/L \text{mmol/L} mmol/L of urea (two nitrogen atoms per urea molecule, atomic weight 14 × 2 = 28 14 \times 2 = 28 14 × 2 = 28 ).

The difference between the laboratory-measured osmolality (freezing point depression) and the calculated osmolality is the Osmolar Gap (normal < 10 mOsm/kg <10\text{ mOsm/kg} < 10 mOsm/kg ):

Osmolar Gap = Measured Osmolality − Calculated Osmolality \text{Osmolar Gap} = \text{Measured Osmolality} - \text{Calculated Osmolality} Osmolar Gap = Measured Osmolality − Calculated Osmolality

An elevated osmolar gap ( > 10 mOsm/kg >10\text{ mOsm/kg} > 10 mOsm/kg ) demonstrates the pathological accumulation of unmeasured low-molecular-weight exogenous toxins in the circulation: methanol (formic acid toxicity, retinal optic disc edema, "snowstorm" vision), ethylene glycol (glycolic/oxalic acid toxicity, acute tubular necrosis, calcium oxalate envelope crystals in urine), isopropanol (acetone generation without metabolic acidosis), or diabetic ketoacidosis (acetone).

The Van 't Hoff Equation & Reflection Coefficients

The osmotic pressure ( Π \Pi Π ) generated by a solution across an ideal semipermeable membrane is dictated by the Van 't Hoff Equation :

Π = σ ⋅ i ⋅ C ⋅ R ⋅ T \Pi = \sigma \cdot i \cdot C \cdot R \cdot T Π = σ ⋅ i ⋅ C ⋅ R ⋅ T

Where:

i i i is the dimensionless van 't Hoff dissociation factor (e.g., i = 1 i = 1 i = 1 for non-ionizing solutes like glucose and urea; i ≈ 1.85 − 2.0 i \approx 1.85-2.0 i ≈ 1.85 − 2.0 for fully dissociating salts like N a C l NaCl N a Cl ).

C C C is molar concentration ( mol/L \text{mol/L} mol/L ).

R R R is the gas constant, and T T T is absolute temperature.

σ \sigma σ (Staverman's Reflection Coefficient): A critical dimensionless index ranging from 0.0 to 1.0 0.0\text{ to } 1.0 0.0 to 1.0 that quantifies the membrane's permeability to a specific solute:

σ = 1.0 \sigma = 1.0 σ = 1.0 (Complete Impermeability): The membrane is entirely impermeable to the solute. The solute is fully "reflected" at the membrane interface, generating 100 % 100\% 100% of its theoretical thermodynamic osmotic pressure. Examples include serum albumin across continuous capillary endothelium, and intracellular potassium across the sarcolemma.

σ = 0.0 \sigma = 0.0 σ = 0.0 (Complete Permeability): The membrane is freely, instantaneously permeable to the solute ( P solute = P water P_{\text{solute}} = P_{\text{water}} P solute ​ = P water ​ ). The solute diffuses across the membrane as rapidly as water, equalizing its concentration between compartments without creating a transcellular osmotic pressure gradient. Example: urea and ethanol across mammalian cell membranes.

0 < σ < 1.0 0 < \sigma < 1.0 0 < σ < 1.0 (Partial Permeability): Intermediate behavior. For example, sodium chloride exhibits σ ≈ 0.95 \sigma \approx 0.95 σ ≈ 0.95 across peripheral capillary endothelium, but σ = 1.0 \sigma = 1.0 σ = 1.0 across cellular plasma membranes.

Effective Osmoles vs. Ineffective Osmoles: The Concept of Tonicity

Tonicity is not synonymous with total osmolality. Whereas osmolality measures the total concentration of all dissolved solute particles regardless of whether they can permeate the membrane, Tonicity (Effective Osmolality) depends exclusively on the concentration of impermeant, effective osmoles (where σ → 1.0 \sigma \to 1.0 σ → 1.0 ):

Effective Osmoles: Solutes that cannot cross the plasma membrane unassisted (e.g., N a + Na^+ N a + , K + K^+ K + , mannitol, and glucose in the absence of insulin). These solutes exert a sustained osmotic draw, forcing water to shift across the cell membrane until intracellular and extracellular osmolalities equalize.

Ineffective Osmoles: Solutes that cross cell membranes freely down their own concentration gradients (e.g., urea and ethanol ). When blood urea nitrogen spikes (as in severe uremic renal failure), urea diffuses equally into both the ICF and ECF. Because urea concentrations become identical on both sides of the cell membrane, urea generates zero transcellular osmotic gradient and causes no net water movement or change in cell volume . Tonicity Effects on Cell Volume

  • HYPOTONIC SOLUTION ISOTONIC SOLUTION HYPERTONIC SOLUTION
  • (<280 mOsm/kg) (285-295 mOsm/kg) (>300 mOsm/kg)
  • ────────────────── ───────────────── ───────────────────
  • H2O H2O H2O H2O
  • │ │ ▲ ▲
  • ▼ ▼ │ │
  • ┌─────────┐ ┌───────────────┐ ┌───────┐
  • │ │ │ │ │ / \ │
  • │ SWELL │ │ NORMAL │ │ CREN- │
  • │ & LYSE │ │ ERYTHROCYTE │ │ ATE │
  • │ │ │ │ │ \ / │
  • └─────────┘ └───────────────┘ └───────┘
  • Water Enters Cell Dynamic Equilibrium Water Leaves Cell
  • (0.45% Saline / D5W) (0.9% Normal Saline) (3% Saline / Mannitol)
  • Clinical Intravenous Solutions & Cellular Volume Dynamics

Isotonic Solutions ( 285 − 295 mOsm/kg 285 - 295\text{ mOsm/kg} 285 − 295 mOsm/kg ):

0.9% Normal Saline ( N a C l NaCl N a Cl , 308 mOsm/L 308\text{ mOsm/L} 308 mOsm/L ): Contains 154 mEq/L N a + 154\text{ mEq/L } Na^+ 154 mEq/L N a + and 154 mEq/L C l − 154\text{ mEq/L } Cl^- 154 mEq/L C l − . Because sodium is excluded from the intracellular compartment by the N a + / K + Na^+/K^+ N a + / K + ATPase ( σ = 1.0 \,\sigma = 1.0 σ = 1.0 ), infused normal saline remains entirely within the extracellular fluid (ECF), expanding the intravascular and interstitial spaces without producing net water flux into or out of cells.

Lactated Ringer's Solution ( 273 mOsm/L 273\text{ mOsm/L} 273 mOsm/L ): Contains physiological concentrations of N a + Na^+ N a + ( 130 130 130 ), C l − Cl^- C l − ( 109 109 109 ), lactate ( 28 28 28 ), K + K^+ K + ( 4 4 4 ), and C a 2 + Ca^{2+} C a 2 + ( 2.7 2.7 2.7 ). Ideal physiological crystalloid for perioperative podiatric fluid resuscitation.

Hypotonic Solutions ( < 280 mOsm/kg <280\text{ mOsm/kg} < 280 mOsm/kg ):

0.45% Half-Normal Saline ( 154 mOsm/L 154\text{ mOsm/L} 154 mOsm/L ) or 5% Dextrose in Water (D5W, 278 mOsm/L 278\text{ mOsm/L} 278 mOsm/L ): In the IV bag, D5W is iso-osmolar; however, once infused, dextrose is immediately transported into cells via insulin/GLUT4 and metabolized to C O 2 CO_2 C O 2 ​ and H 2 O H_2O H 2 ​ O , effectively leaving behind pure free water. Free water dilutes extracellular osmolality, creating a transcellular osmotic gradient driving water into cells . Causes cellular swelling ; if administered excessively, poses a severe risk of cerebral edema and erythrocyte lysis.

Hypertonic Solutions ( > 300 mOsm/kg >300\text{ mOsm/kg} > 300 mOsm/kg ):

3% Hypertonic Saline ( 1 , 026 mOsm/L 1,026\text{ mOsm/L} 1 , 026 mOsm/L ) or 20% Mannitol ( 1 , 100 mOsm/L 1,100\text{ mOsm/L} 1 , 100 mOsm/L ): Elevates ECF effective osmolality far above ICF levels. Water is rapidly drawn out of the intracellular compartment into the vascular tree down the osmotic gradient, producing cellular dehydration (crenation) .

Podiatric Application: Mannitol ( σ = 1.0 \,\sigma = 1.0 σ = 1.0 ) is administered parenterally to reduce acute post-traumatic interstitial and intracompartmental pressures in limb-threatening lower extremity acute compartment syndrome following calcaneal crush injuries or high-energy pilon fractures before definitive surgical fasciotomy can be achieved.

Note

SGLT2 Inhibitor Glycosuria in Podiatric Clinical Care: SGLT2 inhibitors (e.g., empagliflozin) lower blood glucose by inducing osmotic glycosuria through targeted blockade of proximal tubular secondary active transport. While delivering remarkable renal filtration preservation and cardiovascular mortality reduction, clinicians must maintain rigorous surveillance for euglycemic diabetic ketoacidosis (euDKA) and severe pedal dehydration in diabetic patients with peripheral sensory neuropathy and peripheral arterial disease undergoing foot surgery.